Sanofi $SNY Position Decreased by Brandywine Global Investment Management LLC

Key Points

• Brandywine Global Investment Management LLC has reduced its stake in Sanofi (NASDAQ:SNY) by 6.5%, owning 733,129 shares worth approximately $40.7 million after selling 50,687 shares in the first quarter.
• JPMorgan Chase & Co. upgraded Sanofi's rating from "neutral" to "overweight", while the stock has an average rating of "Buy" and a target price of $62.00.
• Sanofi reported earnings of $0.90 per share for the last quarter, missing analysts' estimates, with revenues of $11.34 billion, down 7% compared to the previous year.

Brandywine Global Investment Management LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 6.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 733,129 shares of the company's stock after selling 50,687 shares during the period. Brandywine Global Investment Management LLC's holdings in Sanofi were worth $40,659,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Cardinal Capital Management grew its holdings in Sanofi by 0.3% during the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock worth $3,827,000 after acquiring an additional 199 shares in the last quarter. Gradient Investments LLC grew its holdings in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after purchasing an additional 200 shares during the last quarter. Perigon Wealth Management LLC raised its position in Sanofi by 3.1% in the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares during the last quarter. Beacon Financial Group lifted its position in Sanofi by 1.6% during the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock worth $799,000 after acquiring an additional 222 shares during the period. Finally, AdvisorNet Financial Inc grew its position in Sanofi by 16.4% in the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock valued at $89,000 after buying an additional 227 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 0.7%

Shares of SNY stock traded up $0.35 during trading hours on Tuesday, hitting $50.19. 1,734,010 shares of the company were exchanged, compared to its average volume of 2,577,855. The stock has a market capitalization of $123.24 billion, a price-to-earnings ratio of 12.06, a P/E/G ratio of 1.19 and a beta of 0.48. Sanofi has a one year low of $44.73 and a one year high of $60.12. The business's 50-day simple moving average is $48.57 and its two-hundred day simple moving average is $51.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.73 earnings per share. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $62.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.